Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications
Experimental Biology and Medicine · 12.12.2025 · 250
DOI: 10.3389/ebm.2025.10784 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 12.12.2025. Verfasst von Saumya Nishanga Heendeniya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia. Hauptthemen laut MEDLINE: RNA, Messenger, Drug Design, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn’t integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5′cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA’s molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.
- Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.
Zitieren
APA
Heendeniya, S. N., Chen, S., Bhatti, S., Zahra, Q. U. A., Rahimizadeh, K., Poudel, B. H., Wilton, S. D., & Veedu, R. N. (2025). Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications. Experimental Biology and Medicine, 250. https://doi.org/10.3389/ebm.2025.10784
Vancouver
Heendeniya SN, Chen S, Bhatti S, Zahra QUA, Rahimizadeh K, Poudel BH, et al. Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications. Experimental Biology and Medicine. 2025;250. doi:10.3389/ebm.2025.10784
BibTeX
@article{Heendeniya2025,
author = {Heendeniya, Saumya Nishanga and Chen, Suxiang and Bhatti, Saadia and Zahra, Qurat Ul Ain and Rahimizadeh, Kamal and Poudel, Bal Hari and Wilton, Stephen D and Veedu, Rakesh N},
title = {Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications},
journal = {Experimental Biology and Medicine},
year = {2025},
volume = {250},
doi = {10.3389/ebm.2025.10784}
}
EUVIMED